Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Aging Kairos: treating older Hodgkin patients

Daniel Molin

Blood (2024) 143 (11): 943–945.

https://doi.org/10.1182/blood.2023023125

Published: 2024

Journal Articles

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Blood (2023) 142 (10): 878–886.

https://doi.org/10.1182/blood.2022019386

Published: 2023

Includes: Supplemental data

Journal Articles

NLPHL: a hummingbird in an owl’s nest

Daniel Molin

Blood (2023) 142 (6): 499–500.

https://doi.org/10.1182/blood.2023021091

Published: 2023

Journal Articles

Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Joachim Baech, Lasse Hjort Jakobsen, Tarec Christoffer Christoffer El-Galaly, Daniel Molin, Ingrid Glimelius, Joshua P.P. Entrop, Michael Crowther, Karin Ekstroem Smedby, Sandra Eloranta, Caroline E. Weibull

Blood (2022) 140 (Supplement 1): 9411–9412.

https://doi.org/10.1182/blood-2022-157279

Published: 2022

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Stefano Luminari, Alexander Fosså, Judith Trotman, Daniel Molin, Francesco Annibale d'Amore, Gunilla Enblad, Leanne Berkahn, Sally F Barrington, John Radford, Massimo Federico, Amy A. Kirkwood, Peter Johnson

Blood (2022) 140 (Supplement 1): 766–767.

https://doi.org/10.1182/blood-2022-162780

Published: 2022

Journal Articles

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Philippe Armand, Pier Luigi Luigi Zinzani, Hun Ju Lee, Nathalie Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Blood (2021) 138 (Supplement 1): 1366.

https://doi.org/10.1182/blood-2021-147881

Published: 2021

Journal Articles

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie Johnson, MD, Pauline Brice, John Radford, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, MD PhD, Bastian Von Tresckow, Margaret A. Shipp, MD, Alex F. Herrera, MD, Jianxin Lin, Eunhee Kim, Mohammed Farooqui, Patricia Marinello, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 240.

https://doi.org/10.1182/blood-2019-127280

Published: 2019

Journal Articles

Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients

Blood (2019) 134 (Supplement_1): 4113.

https://doi.org/10.1182/blood-2019-127995

Published: 2019

Journal Articles

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz

Blood (2019) 134 (14): 1144–1153.

https://doi.org/10.1182/blood.2019000324

Published: 2019

Includes: Supplemental data

Journal Articles

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, MD, Robert W. Chen, MD, Hun Ju Lee, MD, Philippe Armand, MD PhD, Nathalie A Johnson, MD PhD, Pauline Brice, MD, John Radford, MD FRCP, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian Von Tresckow, MD, Margaret A. Shipp, MD, Eunhee Kim, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2018) 132 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2018-99-117045

Published: 2018

Journal Articles

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Boris Boell, MD, Alexander Fosså, MD PhD, Helen Goergen, Peter Kamper, Sirpa Leppa, MD Prof, Daniel Molin, Julia Meissner, MD, Ellen Ritter, MD, Jacob H. Christensen, Martin Hutchings, MD, Michael Fuchs, Andreas Engert, MD, Carsten Kobe, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 926.

https://doi.org/10.1182/blood-2018-99-119363

Published: 2018

Journal Articles

Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients

Lasse H. Jakobsen, Fredrik Ellin, Knut B. Smeland, Tove Wästerlid, Jacob H. Christensen, Judit Jørgensen, MD PhD, Pär L. Josefsson, Harald Holte, Jr., MD PhD, Yngvild N. Blaker, Jacob H. Grauslund, Jon Bjørn, Daniel Molin, Ingemar Lagerlöf, MD, Karin Ekstroem Smedby, MDPhD, Katherine Colvin, Gita Thanarajasingam, MD, Alina S. Gerrie, MD MPH, Chan Y. Cheah, Tarec C. El-Galaly

Blood (2018) 132 (Supplement 1): 452.

https://doi.org/10.1182/blood-2018-99-111748

Published: 2018

Journal Articles

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

Craig H. Moskowitz, MD, Pier Luigi Zinzani, MD PhD, Michelle A. Fanale, MD, Philippe Armand, MD PhD, Nathalie A. Johnson, John A. Radford, MD, Vincent Ribrag, MD, Daniel Molin, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian von Tresckow, MD, Margaret A. Shipp, MD, Eric Gustafson, PhD, Yinghua Zhang, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM, Robert W Chen, MD

Blood (2016) 128 (22): 1107.

https://doi.org/10.1182/blood.V128.22.1107.1107

Published: 2016

Journal Articles

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

Blood (2016) 127 (12): 1531–1538.

https://doi.org/10.1182/blood-2015-11-679407

Published: 2016

Includes: Supplemental data

Journal Articles

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Lars C. Gormsen, Cecilia Wassberg, Daniel Molin, Peter Kamper, Gunilla Enblad, Francesco d'Amore

Blood (2014) 124 (21): 5360.

https://doi.org/10.1182/blood.V124.21.5360.5360

Published: 2014

NARROW

Aging Kairos: treating older Hodgkin patients

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

NLPHL: a hummingbird in an owl’s nest

Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only